Adage Capital Partners’s Opus Genetics IRD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$10.9M Sell
2,254,996
-3,774,779
-63% -$15.7M 0.02% 701
2026
Q2
$24.8M Hold
6,029,775
– – 0.03% 439
2026
Q1
$27.4M Buy
6,029,775
+4,924,779
+446% +$17M 0.04% 384
2025
Q4
$2.22M Buy
1,104,996
+150,000
+16% +$305K ﹤0.01% 829
2025
Q3
$1.58M Buy
+954,996
New +$1.19M ﹤0.01% 820

Other funds holding IRD

Adage Capital Partners's IRD Position: Q3 2026 in Review

Adage Capital Partners reduced its Opus Genetics (IRD) stake by 63% in Q3 2026, selling an estimated $15.7M and leaving 2,254,996 shares worth $10.9M. The position accounts for 0.02% of the portfolio, ranked #701.

Adage Capital Partners first reported a position in IRD in Q3 2025 and has held it in 5 quarters since. The position peaked at $27.4M in Q1 2026. 91 funds tracked by Wall St. Rank hold IRD as of Q3 2026.

  • Adage Capital Partners held 2,254,996 shares of Opus Genetics worth $10.9M as of Q3 2026.
  • Adage Capital Partners sold 3,774,779 Opus Genetics shares in Q3 2026, an estimated $15.7M.
  • Opus Genetics made up 0.02% of Adage Capital Partners's portfolio in Q3 2026, its #701 holding.
  • Adage Capital Partners first reported a position in Opus Genetics in Q3 2025 and has held it in 5 quarters since.
  • Adage Capital Partners's Opus Genetics position peaked at $27.4M in Q1 2026.
  • 91 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2026.

Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.